LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Healthineers Demonstrates Power of Data with Atellica Diagnostics IT Solutions

By LabMedica International staff writers
Posted on 05 Aug 2019
Image: The Atellica Diagnostics IT portfolio is helping labs manage increasing workloads, staffing challenges, and decreasing budgets with innovative data-driven solutions (Photo courtesy of Siemens Healthineers).
Image: The Atellica Diagnostics IT portfolio is helping labs manage increasing workloads, staffing challenges, and decreasing budgets with innovative data-driven solutions (Photo courtesy of Siemens Healthineers).
Siemens Healthineers (Erlangen, Germany) demonstrated the power of leveraging data to unlock a laboratory’s full potential by showcasing its Atellica Diagnostics IT portfolio at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo. At AACC 2019, the company featured its innovative IT solutions to combat the laboratory’s staffing challenges, limited budgets, and the increasing complexity in sample management and testing.

The Siemens Healthineers Atellica Diagnostics IT portfolio enables laboratories to unlock their full potential by leveraging data to optimize workflows. With easy-to-navigate user interfaces and centralized management of operations, the robust software solution enhances visibility into valuable business analytics that unify sample, process, result, and inventory data. These features have enabled laboratories to achieve a 93% reduction in testing errors, an 85% increase in patient and staff satisfaction, and an 88% achievement rate for 30-minute STAT turnaround.

The Atellica portfolio pipeline includes the Atellica Asa Application, a tablet-based virtual assistant designed to simplify and organize operator interactions with the instruments. The goal of the Atellica Asa Application is to draw staff attention to a single interface with only the most common, yet critical, procedures needed to complete daily system operations. The tile-based software is designed to organize operator tasks by workflow and to reduce the number of screens used to complete a single task.

In addition to demonstrations of the Atellica Asa virtual assistant, attendees learned more about LifeNet, an online program that helps labs increase system utilization by providing a centralized platform to schedule system maintenance and view service history of connected Siemens Healthineers systems. Attendees also explored the artificial intelligence-driven Guardian Program, which can help to predict certain system failures up to 21 days before they happen. By monitoring more than 80 critical components in real time, the Guardian Program can continuously detect potential issues and schedule repairs at a time that will not affect turnaround time, maintaining workflow during peak hours. Visitors to the Siemens Healthineers booth also experienced their own virtual reality journey through a simulated hospital environment to visualize in vitro testing and workflow possibilities based upon tailored needs.

Additionally, Siemens Healthineers unveiled its newest technology for point-of-care testing—the RAPIDPoint 500e Blood Gas System—for product demonstration at the event.

“Point-of-care testing enables clinicians to deliver the right test in the right setting for their patients at the right time,” said Christoph Pedain, PhD, Head of Point-of-Care Diagnostics, Siemens Healthineers.

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Alcohol Testing Device
Dräger Alcotest 7000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more